Bioactive components conjugated to substrates of microneedle arrays
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsLouis D. Falo, Jr., Geza Erdos
Life of this patent
Estimating the term…
Abstract
Microneedle arrays and methods of forming the same can include one or more bioactive components bonded to a biocompatible material such that the one or more bioactive components are cleavable in vivo to release the bioactive component from the biocompatible material.
Claims64
A dissolvable microneedle array for transdermal insertion into a patient comprising:
- a substrate comprising a biocompatible material that forms base portion and a plurality of microneedles extending from the base portion;
- and
- one or more bioactive components conjugated to the biocompatible material,
- wherein the one or more bioactive components are cleavable in vivo by an enzyme to release the bioactive component from the biocompatible material, or the bioactive component retains function when conjugated to the biocompatible material.
A dissolvable microneedle array for transdermal insertion into a patient comprising:
- a substrate comprising a biocompatible material that forms base portion and a plurality of microneedles extending from the base portion;
- and
- a first bioactive component conjugated to the biocompatible material, the bioactive component being Doxorubicin,
- wherein the first bioactive component is cleavable in vivo by an enzyme to release the first bioactive component from the biocompatible material, or the first bioactive component retains function when conjugated to the biocompatible material.
A dissolvable microneedle array for transdermal insertion into a patient comprising:
- a substrate comprising a biocompatible material that forms base portion and a plurality of microneedles extending from the base portion;
- and
- one or more bioactive components conjugated to the biocompatible material,
- wherein the one or more bioactive components are cleavable in vivo to release the bioactive component from the biocompatible material, or the bioactive component retains function when conjugated to the biocompatible material, and
- wherein the one or more bioactive components are bonded to the biocompatible material by a disulfide bond which is cleavable in vivo by an enzyme.
A dissolvable microneedle array for transdermal insertion into a patient comprising:
- a substrate comprising a biocompatible material that forms base portion and a plurality of microneedles extending from the base portion;
- and
- one or more bioactive components conjugated to the biocompatible material,
- wherein the one or more bioactive components are cleavable in vivo by an enzyme to release the bioactive component from the biocompatible material, or the bioactive component retains function when conjugated to the biocompatible material, and
- wherein the one or more bioactive component comprises at least one viral vector wherein the bioactive component is bonded to the biocompatible material by a disulfide bond which is cleavable in vivo by an enzyme.
A dissolvable microneedle array for transdermal insertion into a patient comprising:
- a substrate comprising a biocompatible material that forms base portion and a plurality of microneedles extending from the base portion;
- and
- one or more bioactive components conjugated to the biocompatible material,
- wherein the one or more bioactive components are cleavable in vivo to release the bioactive component from the biocompatible material, or the bioactive component retains function when conjugated to the biocompatible material,
- wherein the one or more bioactive components comprise at least two different bioactive components conjugated to the biocompatible material, and
- wherein the bioactive component comprises an antigen and an adjuvant for a vaccine application.
A dissolvable microneedle array for transdermal insertion into a patient comprising:
- a substrate comprising a biocompatible material that forms base portion and a plurality of microneedles extending from the base portion;
- and
- a first bioactive component conjugated to the biocompatible material, the bioactive component being Doxorubicin,
- wherein the first bioactive component is cleavable in vivo to release the first bioactive component from the biocompatible material, or the first bioactive component retains function when conjugated to the biocompatible material, and
- wherein the second bioactive component is mixed into the biocompatible material wherein the bioactive components are bonded to the biocompatible material by a disulfide bond which is cleavable in vivo by an enzyme.
Dependencies are inferred from the claim text.